Assessment of Potential Adverse Events Following the 2022–2023 Seasonal Influenza Vaccines Among U.S. Adults Aged 65 Years and Older
Authors:
- Xiangyu (Chianti) ShiXSXiangyu (Chianti) Shi
- Joann F. GruberJGJoann F. Gruber
- Michelle OndariMOMichelle Ondari
- Patricia C. LloydPLPatricia C. Lloyd
- Pablo Freyria DuenasPDPablo Freyria Duenas
- Tainya C. ClarkeTainya C. Clarke
- Gita NadimpalliGNGita Nadimpalli
- Sylvia ChoSCSylvia Cho
- Laurie FeinbergLFLaurie Feinberg
- Mao HuMHMao Hu
- Yoganand ChillarigeYCYoganand Chillarige
- Jeffrey A. KelmanJKJeffrey A. Kelman
Preprint
Abstract
Background: While safety of influenza vaccines is well-established, some studies have suggested potential associations between influenza vaccines and certain adverse events (AEs). This study examined the safety of the 2022–2023 influenza vaccines among U.S. adults ≥ 65 years. Methods: A self-controlled case series compared incidence rates of anaphylaxis, encephalitis/encephalomyelitis, Guillain Barré-Syndrome (GBS), and transverse myelitis following 2022–2023 seasonal influenza vaccinations (i.e., any, high-dose or adjuvanted) in risk and control intervals among Medicare beneficiaries ≥ 65 years. We used conditional Poisson regression to estimate incidence rate ratios (IRRs) and 95% confidence intervals (CIs) adjusted for event-dependent observation time, seasonality, and outcome misclassification. For AEs with any statistically significant associations, we stratified results by concomitant vaccination status. Results: Among 12.7 million vaccine recipients, we observed 76 anaphylaxis, 276 encephalitis/encephalomyelitis, 134 GBS and 75 transverse myelitis cases. Only rates of anaphylaxis were elevated in risk compared to control intervals. With all adjustments, an elevated, but non-statistically significant, anaphylaxis rate was observed following any (IRR: 2.40, 95% CI: 0.96–6.03), high-dose (IRR: 2.31, 95% CI: 0.67–7.91), and adjuvanted (IRR: 3.28, 95% CI: 0.71–15.08) influenza vaccination; anaphylaxis IRRs were 2.54 (95% CI: 0.49–13.05) and 1.64 (95% CI: 0.38–7.05) for those with and without concomitant vaccination, respectively. Conclusions: Rates of encephalitis/encephalomyelitis, GBS, or transverse myelitis were not elevated following 2022–2023 seasonal influenza vaccinations among U.S. adults ≥ 65 years. There was an increased rate of anaphylaxis following influenza vaccination that may have been influenced by concomitant vaccination.Keywords
All Related Versions
- Published version: Vaccine, 42 (15), 3486.
This publication has 31 references indexed in Scilit:
- Risk of anaphylaxis after vaccination in children and adultsJournal of Allergy and Clinical Immunology, 2016
- Absence of associations between influenza vaccines and increased risks of seizures, Guillain–Barré syndrome, encephalitis, or anaphylaxis in the 2012–2013 seasonPharmacoepidemiology and Drug Safety, 2014
- Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccineVaccine, 2013
- Evaluating the safety of influenza vaccine using a claims-based health systemVaccine, 2013
- Acute Disseminated Encephalomyelitis following Seasonal Influenza Vaccination in an Elderly PatientClinical and Vaccine Immunology, 2013
- Longitudinally Extensive Transverse Myelitis Following Vaccination With Nasal Attenuated Novel Influenza A(H1N1) VaccineArchives of Neurology, 2010
- Guillain-Barré Syndrome after Vaccination in United States: Data From the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005)Journal of Clinical Neuromuscular Disease, 2009
- Anaphylaxis in Olmsted County: Seasonal pattern and suggestions for epidemiologic analysisJournal of Allergy and Clinical Immunology, 2009
- Guillain‐Barré Syndrome and Influenza Virus InfectionClinical Infectious Diseases, 2009
- Multiple Imputation for Interval Estimation From Simple Random Samples With Ignorable NonresponseJournal of the American Statistical Association, 1986